High titer multiple dose therapy with HBIG in newborn infants of HBsAg positive mothers

Jhaveri, Ramesh; Rosenfeld, Warren; Salazar, Jorge; Dosik, Harvey; Cheng, Chau-Chie; Evans, Hugh E.

doi:10.1016/s0022-3476(80)80503-8

Cited by 15 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were the background for the conduct of other studies, eight of which were controlled [3,11,22,33,41,60,62,69], and six uncontrolled [34,37,44,63,80,82]. Their results will be discussed here only in summary form; the reader is referred elsewhere for details.…”

Section: Immuimoprophylaxis Of Type B Hepatitis: Clinical Trialsmentioning

confidence: 84%

See 1 more Smart Citation

Immunoprophylaxis and Treatment of Viral Hepatitis B

Seeff¹

1981

Semin Liver Dis

View full text Add to dashboard Cite

It is evident that new vistas have been opened with the advent of antiviral and other novel drugs. Most of the studies performed to date, however, have involved too few patients, have not been double-blinded, or have been entirely uncontrolled. In essence, these represent phase II studies. Because the HBsAg-carrier state is dynamic in that viral markers are generally in a state of flux, and because it is important to determine risk as well as benefit, no conclusions can be reached without an adequately designed double-blind, controlled study. At present, the most promising therapy seems to be the antiviral drugs, particularly interferon and Ara-A (or Ara-AMP). Still to be determined are the appropriate dose, appropriate duration of treatment, the extent of toxicity, and the validity of combination therapy. Also important is the development of simpler and less expensive ways of producing interferon. A potentially exciting and productive era appears about to open.

show abstract

Section: Immuimoprophylaxis Of Type B Hepatitis: Clinical Trialsmentioning

confidence: 84%

“…In another, a single dose of HBIG was reported to prevent transmission [44]. In three studies, success was claimed with the use of multiple doses of HBIG over an extended period [34,37,63]. These promising results require confirmation by appropriately designed double-blind, controlled trials.…”

Section: Post-exposure Prophylaxis Trials (Sexual Contact and "Needlementioning

confidence: 99%

Immunoprophylaxis and Treatment of Viral Hepatitis B

Seeff¹

1981

Semin Liver Dis

View full text Add to dashboard Cite

show abstract

“…Subsequently, human γ-globin preparations purified from sera were injected im to prevent paralytic disease caused by polio (9). In the 1970s, it was observed that one could achieve 70-100% efficacy in preventing transmission of hepatitis B by administration im of immunoglobulins to neonates born to infected mothers (10). The safe im doses were limited to about 100-150 mg/kg body weight (11).…”

Section: Historical Perspective Of Passive Immunization Studies For Pmentioning

confidence: 99%

Passive immunization for immunocontraception: lessons learned from infectious diseases

Naz

Rajesh²

2004

Front Biosci

View full text Add to dashboard Cite

Development of vaccine for contraception is an exciting proposition that could provide a valuable alternative to the presently available methods for birth control. Various targets such as gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH), leutinizing hormone (LH), zona pellucida (ZP) antigens, sperm antigens, and human chorionic gonadotropin (hCG) are being explored for immunocontraception. Besides specific concerns associated with each contraceptive vaccine, the progress has been restricted by the variability of the immune response after active immunization, attain and maintain high antibody titers, time lag to achieve reasonably good antibody titers, and uncertainty regarding how long the bioeffective antibodies will remain in circulation. It is envisaged that these concerns may be taken care of by using the preformed antibodies in the passive immunization approach. The antibody therapies have been tried and found to be successful against various infectious diseases both in animals as well as humans. Some have become treatment modalities in the clinics. This manuscript will review the data available for the passive immunization of preformed polyclonal and murine/humanized/human monoclonal antibodies, their efficacy, mode of delivery, duration of the effects, and limitations, if any. The overall objective is to examine the feasibility and practicability of the passive immunization approach for immunocontraception.

show abstract

Pediatric Immunizations

Marks

1985

Pediatric Infectious Diseases for the Practitioner

View full text Add to dashboard Cite

High titer multiple dose therapy with HBIG in newborn infants of HBsAg positive mothers

Cited by 15 publications

References 10 publications

Immunoprophylaxis and Treatment of Viral Hepatitis B

Immunoprophylaxis and Treatment of Viral Hepatitis B

Passive immunization for immunocontraception: lessons learned from infectious diseases

Pediatric Immunizations

Contact Info

Product

Resources

About